Toni Beninato
NewYork–Presbyterian Hospital
Publications 50
#1Dessislava Stefanova (NewYork–Presbyterian Hospital)
#2Arpita Bose (NewYork–Presbyterian Hospital)
Last.Toni Beninato (NewYork–Presbyterian Hospital)H-Index: 10
view all 0 authors...
Background The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.
#1Timothy M. Ullmann (NewYork–Presbyterian Hospital)H-Index: 1
#2Katherine D. Gray (NewYork–Presbyterian Hospital)H-Index: 2
Last.Toni Beninato (NewYork–Presbyterian Hospital)H-Index: 10
view all 0 authors...
#1Timothy M. Ullmann (NewYork–Presbyterian Hospital)H-Index: 1
#2Heng Liang (NewYork–Presbyterian Hospital)
Last.Toni Beninato (NewYork–Presbyterian Hospital)H-Index: 10
view all 0 authors...
Abstract Background The majority of papillary thyroid cancers are driven by acquired mutations typically in the BRAF or RAS genes that aberrantly activate the mitogen-activated protein kinase pathway. This process leads to malignant transformation, dedifferentiation, and a decrease in the expression of the sodium-iodide symporter (NIS; SLC5A5), which results in resistance to radioactive iodine therapy. We sought to determine whether inhibition of aberrant mitogen-activated protein kinase-signali...
#1Timothy M. Ullmann (Cornell University)H-Index: 1
#2Katherine D. Gray (Cornell University)H-Index: 2
Last.Toni Beninato (Cornell University)H-Index: 10
view all 10 authors...
Background Health insurance has been shown to be a key determinant in cancer care, but it is unknown to what extent insurance status affects treatments provided to papillary thyroid cancer (PTC) pa...
#2Maheshwaran Sivarajah (SBMC: Saint Barnabas Medical Center)
Last.Thomas J. FaheyH-Index: 40
view all 0 authors...
Abstract Background Primary aldosteronism is a common cause of secondary hypertension. Treatment with adrenalectomy or mineralocorticoid receptor-blockers can prevent long-term adverse outcomes. This study aimed to determine primary aldosteronism screening rats in patients with hypertension in an underserved urban healthcare system. Methods We reviewed records of outpatient adults in an urban healthcare system from 2013 to 2017. Chart review along with International Statistical Classification of...